Mereo BioPharma Group plc

Mereo BioPharma Group plc is a biopharmaceutical company that develops therapeutics for rare diseases. The organization acquires drug candidates with prior development history from larger pharmaceutical corporations to advance clinical programs. Its principal late-stage clinical assets include setrusumab, a monoclonal antibody under evaluation for osteogenesis imperfecta, and alvelestat, an oral neutrophil elastase inhibitor designed for alpha-1 antitrypsin deficiency-associated lung disease. It also maintains vantictumab for autosomal dominant osteopetrosis Type 2. The company focuses on clinical-stage segments, serving patient populations with specialized medical conditions and collaborating with commercial biopharmaceutical partners.

The company conducts development activities across the United Kingdom and the United States, coordinating clinical trials through specialized clinical sites and contract research organizations. It partners with global life sciences firms, retaining commercial rights to specific programs in Europe and the United Kingdom. Mereo BioPharma Group plc maintains its principal executive offices in London, United Kingdom.

Summary of the business section of Mereo BioPharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, Mereo had 39 employees.”